Sponsor oversight and clinical operations
Small Biotech First-Trial Readiness: Connect Monitoring to Sponsor Decisions
Plan sponsor decision ownership, CRA responsibilities, escalation and follow-up before a small biotech’s first oncology trial.
By Lampgen Clinical Research

5 min read · estimated
What the source reported
Jessica Cordes’ October 26, 2026 Clinical Leader commentary addresses organizational preparation for a small biotech’s first trial. It prompted Lampgen’s proposed handoff exercise below; this is operational analysis, not new clinical evidence. [1]
ICH E6(R3), Annex 1, sections 3.6.6 and 3.6.9, addresses the sponsor’s ultimate responsibility and oversight of important work transferred to service providers. Section 3.9.5 calls for oversight suited to trial complexity and risk. FDA issued its E6(R3) final guidance in September 2025. [2, 3]
Define what a finding needs to become a decision
For a small sponsor, an additional monitoring resource can add important capacity. The assignment also needs a place in the study’s decision process. A useful monitoring finding should reach the appropriate reviewer with enough context to assess its significance and choose a response.
Lampgen’s proposed planning exercise is to select one consequential procedure and trace its failure pathway. Identify who observes the issue, who investigates it, who assesses the implications, who can authorize action and who verifies the result. Use actual roles and contact routes rather than a list of departments.
Clinical operations can coordinate that pathway while medical, safety, quality, regulatory and other functions retain their relevant responsibilities. The exercise should make boundaries of authority clear, including when investigator judgment or a formal committee decision is required.
Illustrative case: repeated PK-window deviations
Consider a hypothetical early oncology study with missed pharmacokinetic collection windows at two sites. PK sampling helps characterize drug exposure. The consequences of a missed time point depend on the study and require the appropriate scientific assessment. This is an illustrative scenario, not a finding from a Lampgen engagement.
A CRA can establish the actual visit sequence, confirm the recorded collection times and investigate the operational cause. A study-level reviewer can check whether the pattern appears elsewhere. The responsible medical and clinical pharmacology teams assess implications for the study; the agreed authorities approve any response.
A response could involve correcting an instruction, addressing a scheduling constraint or preparing a protocol change for required review. The finding alone does not establish which response is appropriate. Monitoring staff should follow the protocol and approved processes.
Before closing the action, define the next evidence to review. Subsequent eligible visits may show whether collection performance improved. When recruitment or exposure is limited, an immediate assessment of effectiveness may be premature. Keep the action under review until the agreed evidence is available.
Translate the exercise into CRA and CTM requirements
1. Specify the protocol experience the assignment requires. Describe the critical procedures, treatment setting, visit complexity and escalation responsibilities. A broad oncology label may not reveal whether someone has managed the relevant operational challenge.
2. Assess how the professional investigates. Ask for an example of establishing what happened, separating an isolated event from a wider pattern and communicating the information that a decision-maker needed. Respect confidentiality when reviewing prior work.
3. Define the limits of the assignment. Document who can raise a query, request information, coordinate a review and authorize a change. Monitoring does not transfer clinical judgment from investigators or replace the sponsor’s oversight responsibilities.
4. Prepare the working conditions. Confirm access, current study documents, training, review cadence, backup contacts and an escalation route before work begins. These are proposed assignment-planning steps, not a claim of confirmed staffing availability.
Apply SIGNAL™ to the response and the evidence
SIGNAL™ is Lampgen’s six-step framework: Spot, Investigate, Gauge, Name, Act and Learn. In this example, the useful progression is to investigate the missed collections, gauge recurrence, name the specific risk, act through the authorized study process and learn from subsequent evidence.
This is Lampgen’s method of structuring the discussion. It is not an ICH requirement or a validated claim of improved study outcomes. FDA’s risk-based monitoring Q&A supports planning and communication of monitoring results; the precise workflow must fit the actual study. [4]
Leadership can use the completed exercise to distinguish additional workload from an unclear decision process. Either may justify action. The staffing brief and oversight arrangements should describe how the proposed support addresses the observed need.
Measure the response as the study grows
Potential benefits include earlier review of recurring issues, clearer decisions and fewer repeated operational failures. These are intended effects, not demonstrated results from this article. Track measures that connect directly to the action, such as recurrence after intervention and completion of time-sensitive decisions.
Review the model when the study adds sites, countries, cohorts or vendors. A named owner needs enough capacity and information to do the work. A responsibility matrix can remain accurate on paper while the actual review process becomes overloaded.
What this means for trial teams
For emerging sponsors, the useful readiness question is whether a consequential finding can reach the right authority and produce an observable response. Rehearse that pathway before first patient in, then review whether it continues to work.
Lampgen Clinical Research scopes oncology CRA and clinical operations staffing around the study’s responsibilities and critical procedures. The worked SIGNAL™ case linked below shows how a monitoring observation can be examined across sites and followed through an effectiveness check.
Analysis by Tommy Lampley, Jr., M.S., Founder, Lampgen Clinical Research. Published November 16, 2026. The accompanying AI-generated conceptual image does not depict actual study records.
Sources
- Jessica Cordes, Clinical Leader — first-time biotech clinical operations commentary, October 26, 2026
- ICH E6(R3) — final guideline, Annex 1 sections 3.6, 3.9 and 3.10; corrected October 24, 2025
- FDA — E6(R3) Good Clinical Practice, final guidance, September 2025
- FDA — A Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers, April 2023
- Lampgen — worked SIGNAL™ monitoring case
- Lampgen — oncology CRA staffing
- Related guide — first-patient oncology site readiness